3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Conditions
Uterine Cervical Neoplasms
6
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Lung Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Neoplasm Metastasis
2
Cholangiocarcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Oligometastatic Prostate Cancer
1
Neoplasms
1
Metastatic Urothelial Cancer
1
Melanoma
1
Locally Advanced Pancreatic Cancer
1
Locally Advanced Cervical Cancer
1
Liver Neoplasms
1
Liposarcoma
1
Kidney Neoplasms
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
trametinib
6
dabrafenib
6
pembrolizumab
5
lenvatinib
5
Paclitaxel
5
Sorafenib
4
Radiotherapy, Intensity-Modulated
3
Doxorubicin
3
pazopanib
2
atezolizumab
2
aldesleukin
2
Taxes
2
Radiotherapy
2
Nivolumab
2
Everolimus
2
Bevacizumab
2
zimberelimab
1
selpercatinib
1
sargramostim
1
sacituzumab govitecan
1
fosbretabulin
1
fludarabine
1
efatutazone
1
cobimetinib
1
ceritinib
1
cemiplimab
1
cabozantinib
1
abemaciclib
1
Vemurafenib
1
Tamoxifen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Thyroid Carcinoma, Anaplastic
×
zimberelimab
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled